I D Hay
Affiliation: Mayo Clinic
- Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year periodIan D Hay
Division of Endocrinology and Internal Medicine, Mayo Clinic and College of Medicine, Rochester, Minn, USA
Surgery 144:980-7; discussion 987-8. 2008..The study aims were to characterize patients with papillary thyroid microcarcinoma (PTM) and to describe post-surgical outcome...
- Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapyIan D Hay
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic and College of Medicine, Rochester, MN Electronic address
Surgery 154:1448-54; discussion 1454-5. 2013..Ultrasound-guided percutaneous ethanol ablation (UPEA) of neck nodal metastases (NNM) has rarely been reported in papillary thyroid carcinoma (PTC) patients with advanced localized disease...
- Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008Ian D Hay
Division of Endocrinology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
World J Surg 34:1192-202. 2010..Controversy exists regarding the aggressiveness of initial therapy in childhood papillary thyroid cancer (PTC). Few studies with long-term outcome exist and second primary malignancies have rarely been analyzed...
- Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinomaIan D Hay
Mayo Clinic College of Medicine, Endocrinology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Surg Oncol 94:692-700. 2006..This article summarizes the available relevant reported data, and concludes that a selective use of RRA in the postoperative management of FCDC patients is rational, and should actually be encouraged...
- Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000Ian D Hay
Division of Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Trans Am Clin Climatol Assoc 113:241-60. 2002..These data encourage a more selective use of I-131 in PTC management and do not lend support to the current widespread use of RRA in low-risk PTC...
- Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patientsIan D Hay
Department of Internal Medicine, Division of Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
World J Surg 26:879-85. 2002..Increasing use of RRA has not apparently improved the already excellent outcome, achieved before 1970, in low risk (MACIS <6) PTC patients managed by near-total thyroidectomy and conservative nodal excision...
- Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinomaB D Lewis
Department of Radiology, Mayo Clinic and Mayo Foundation, 200 First St, SW, Rochester, MN 55905, USA
AJR Am J Roentgenol 178:699-704. 2002..The objective of this study was to evaluate the technique, efficacy, and side effects of percutaneous ethanol injection in patients with limited cervical nodal metastases from papillary thyroid carcinoma...
- Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?V Fatourechi
Division of Endocrinology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Thyroid 10:573-7. 2000..In 7 patients (9%) the PTS results impacted future decisions regarding plans for subsequent diagnostic scanning and 131I therapy or changed the patient's risk group category...
- Non-Hodgkin's lymphoma of the thyroid: is more than biopsy necessary?C M Pyke
Department of Surgery, Mayo Clinic and Foundation, Rochester, Minnesota 55905
World J Surg 16:604-9; discussion 609-10. 1992..The role of surgery in NHLT is diminishing and advances that will increase complete remission and relapse-free survival will not likely involve more aggressive surgical resections...
- Anaplastic thyroid carcinoma: a 50-year experience at a single institutionB McIver
Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Surgery 130:1028-34. 2001..08). Multimodal therapy, including operation, chemotherapy, and radiotherapy, did not improve survival. CONCLUSIONS: The outlook for patients with ATC remains grim. Novel treatments for ATC are desperately needed...
- Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]T T Nguyen
Divisions of Endocrinology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 85:4354-8. 2000....
- Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptakeM R Castro
Division of Endocrinology and Metabolism, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 86:5627-32. 2001..If confirmed, NIS IS of DTC primary lesions may prove useful in the management of patients with known or suspected metastatic thyroid cancer...
- A multidisciplinary study of the 'yips' phenomenon in golf: An exploratory analysisA M Smith
Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Sports Med 30:423-37. 2000..7 strokes to their scores for 18 holes of golf, and have more forearm electromyogram activity and higher competitive anxiety than nonaffected golfers in both high and low anxiety putting conditions. The aetiology of the yips is not clear...
- Cytogenetic and molecular genetic studies of follicular and papillary thyroid cancersM A Herrmann
Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905
J Clin Invest 88:1596-604. 1991....
- 18F-FDG PET in the management of patients with anaplastic thyroid carcinomaTrond Velde Bogsrud
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
Thyroid 18:713-9. 2008..The objective of this study was to investigate the potential contribution of 18F-FDG PET to the clinical management of patients with ATC...
- The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinomaClive S Grant
Department of Surgery, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
World J Surg 32:708-15. 2008..Our aim was to determine the comparative value of F18-fluorodeoxyglucose positron emission tomography (PET) to US for localization of locoregional recurrence in patients who underwent reoperation for recurrent PTC...
- Management of patients with low-risk papillary thyroid carcinomaIan D Hay
The Division of Endocrinology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55901, USA
Endocr Pract 13:521-33. 2007..To define a rational, cost-effective, simple approach to managing most patients with papillary thyroid cancer (PTC) who are at low-risk of either cause-specific mortality or tumor recurrence...
- ATA Guidelines: do patients with stage I thyroid cancer benefit from (131)I?I Ross McDougall
Thyroid 17:595-6; author reply 596-7. 2007
- The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CTTrond V Bogsrud
Division of Nuclear Medicine, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
Nucl Med Commun 28:373-81. 2007....
- Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancerVahab Fatourechi
Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 87:1521-6. 2002..Therefore, widespread use of empiric RAI therapy for such patients who have a large tumor burden should not be encouraged...
- Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancerJohn M Stulak
Department of Gastrointestinal and General Surgery, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Arch Surg 141:489-94; discussion 494-6. 2006..Postoperative surveillance for recurrent PTC increasingly includes thyrotropin-stimulated thyroglobulin and high-resolution ultrasonography (US). This combination commonly can detect recurrent disease as small as 5 mm...
- Sonography of thyroid nodules: a "classic pattern" diagnostic approachCarl C Reading
Department of Radiology, Division of Ultrasonography, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Ultrasound Q 21:157-65. 2005..These appearances include specific nodules that commonly need fine needle aspiration (FNA)/biopsy, and other nodules that do not usually need FNA/biopsy...
- Long-term trends in thyroid carcinoma: a population-based study in Olmsted County, Minnesota, 1935-1999James P Burke
Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 80:753-8. 2005....
- Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinomaGeoffrey B Thompson
Department of Surgery, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
World J Surg 28:1187-98. 2004....
- 18F-FDG PET of patients with Hürthle cell carcinomaVal J Lowe
Department of Radiology, Division of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
J Nucl Med 44:1402-6. 2003..We reviewed our experience with (18)F-FDG PET in the care of patients with Hürthle cell carcinoma to determine the likelihood of uptake in these cancers and the effect of (18)F-FDG PET on patient care...
- Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 yearsRobert R McWilliams
Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Cancer 98:356-62. 2003..To help contribute to the management of this disease entity, the authors present herein what to their knowledge is the largest series reported to date in which all patients had biopsy proven confirmation of their brain metastases...
- High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor geneKathryn Farrand
Department of Pathology and Molecular Medicine, Wellington School of Medicine, New Zealand
J Clin Endocrinol Metab 87:4715-21. 2002..These data suggest that a TSG, involved in HCC pathogenesis, is contained within the D17S1308-D17S695 interval. There are several potential candidate TSGs in this region that are worthy of further study...
- Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates
Radiology 237:794-800. 2005..The recommendations in this consensus statement, which are based on analysis of the current literature and common practice strategies, are thought to represent a reasonable approach to thyroid nodular disease...
- PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic valueMustafa Sahin
Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
J Clin Endocrinol Metab 90:463-8. 2005..g. during intraoperative frozen section). PPARgamma staining also shows an association with favorable prognosis and may have a role in risk stratification...